Understanding GISTs: Diagnosis, Treatment, and Molecular Insights
- Share via
Key Facts
- GISTs are a rare type of cancer that develops in the digestive tract’s connective tissue, specifically from cells that help regulate muscle contractions.
- GISTs are primarily driven by genetic mutations in the KIT and PDGFRA genes, which lead to uncontrolled cell growth.
- Diagnosis of GISTs involves imaging tests like CT scans, immunohistochemistry (checking for markers like CD117), biopsies, and molecular testing to identify specific genetic mutations.
- Treatment options for GISTs include surgical resection to remove the tumor and targeted therapies using tyrosine kinase inhibitors (TKIs) like imatinib, which block the activity of the KIT protein.
- Understanding the molecular characteristics of GISTs is crucial for tailoring treatment plans and improving patient outcomes.
Gastrointestinal stromal tumors, or GISTs, may be rare but in the world of digestive system tumors, they’re the most common of their kind. Unlike the more familiar adenocarcinomas, GISTs are a type of cancer that develops in the digestive tract from the connective tissue of the GI tract. These tumors can pop up anywhere from the esophagus to the rectum but they’re most often found in the stomach or small intestine.
Despite their rarity, GISTs matter because of their unpredictability—some are benign, others are aggressive. Thanks to advances in molecular biology however, we now know what makes GISTs unique is rooted in their genetics.
Table of Contents
- What is GIST?
- Molecular Characteristics: What Makes GISTs Unique
- Causes and Risk Factors
- Tumor Characteristics
- Diagnosing GIST: From Imaging to Molecular Profiling
- Treatment: Surgery and Smart Drugs
- Closing Thoughts
- References
What is GIST?
Gastrointestinal stromal tumors (GISTs) are a rare type of cancer that occurs in the digestive tract, specifically in the gastrointestinal stromal cells. These tumors are also known as gastrointestinal stromal tumors or gastrointestinal stromal tumours, depending on regional spelling variations. GISTs are a type of soft tissue sarcoma that can be found anywhere in the gastrointestinal tract, including the stomach, small intestine and rectum.
According to the National Comprehensive Cancer Network, GISTs are the most common mesenchymal neoplasms of the gastrointestinal tract. The National Cancer Institute estimates that between 4,000 to 6,000 people are diagnosed with GISTs each year in the United States. Despite their rarity, understanding GISTs is key because of their molecular characteristics and the specific treatment they require.
Molecular Characteristics: What Makes GISTs Unique
At the molecular level GISTs are driven by specific genetic mutations—primarily in the KIT and PDGFRA genes. These genetic mutations cause constant “on” signals for cell growth even when the body isn’t telling those cells to divide. GISTs arise from the smooth muscle pacemaker interstitial cells of Cajal within the gastrointestinal tract, primarily due to mutations in the KIT and PDGFRA genes.
KIT mutations which affect the c-Kit protein (CD117) are seen in the majority of cases. This protein acts like a switchboard operator for cell growth signals.
- PDGFRA mutations are also common and affect a similar signaling pathway. These mutations often result in tumors that behave a bit differently and may respond differently to treatment [11].
Beyond these core mutations, researchers are discovering other key players:
- ETV1, a transcription factor, helps amplify KIT-driven signals.
- SDH-deficient GISTs (short for succinate dehydrogenase) are a distinct subtype often found in younger patients and linked to genetic syndromes.
- Mutations or inactivation of MAX and dystrophin genes are newer findings that hint at more complex tumor biology than previously thought [2].
Causes and Risk Factors
The exact cause of GISTs is unknown but research has shown that genetic mutations play a key role. Most GISTs have KIT or PDGFRA mutations leading to uncontrolled cell growth. These genetic mutations are the primary drivers of GISTs. Risk factors for GISTs include family history of the disease, genetic predispositions and previous radiation exposure. Certain genetic syndromes such as Carney-Stratakis syndrome can also increase the risk of GISTs. Individuals with a history of other cancers such as breast or ovarian cancer may also have an increased risk of GISTs. Understanding these risk factors is key to early detection and management of the disease.
Tumor Characteristics
GISTs can vary greatly in size, location and behavior and understanding these characteristics is crucial for accurate diagnosis and treatment.
Size and Growth Rate
The size of a GIST can range from a few millimeters to several centimeters. Larger tumors are generally more likely to be malignant and may require more aggressive treatment [6]. The growth rate of a GIST can also vary, some tumors grow slowly over time and others rapidly. Tumor size and growth rate are key factors in determining the best treatment approach which may be surgery, targeted therapy or a combination of both. Accurate assessment of these characteristics helps in tailoring the treatment plan to the individual patient.
Location and Spread
GISTs can occur anywhere in the gastrointestinal tract but are most common in the stomach. Tumors in the small intestine or rectum are more likely to be malignant and may require more aggressive treatment. GISTs can spread to other parts of the body such as the liver, lungs and peritoneum through the bloodstream or lymphatic system. [12]
This is called metastatic cancer and can complicate treatment. Imaging tests such as computed tomography (CT) scans, magnetic resonance imaging (MRI) and positron emission tomography (PET) scans are valuable tools in determining the location and extent of tumor spread. These imaging modalities help clinicians develop a treatment plan that manages the primary tumor and any metastatic disease.
Diagnosing GIST: From Imaging to Molecular Profiling
Imaging
Many GISTs are incidental—meaning they’re found while looking for something else. Imaging tests like a CT scan are often the first to flag a possible tumor especially when there’s unexplained abdominal pain or bleeding [1]. The following tests including genetic testing are important in deciding the best treatment approach based on the tumor characteristics.
Immunohistochemistry
To confirm the diagnosis, pathologists look for specific markers in the cancer cells of the tumor:
- CD117 (c-Kit) is positive in over 90% of GISTs.
- CD34, another cell surface protein, is positive in about 70% of cases.
- DOG-1 is a newer marker that helps in tricky cases even when KIT is negative [1], [3].
Biopsy
When imaging raises suspicion, a fine-needle aspiration biopsy—often guided by endoscopic ultrasound—is performed [8]. When a doctor suspects a condition during an examination for unrelated issues, it can prompt further testing for GISTs. This provides a tissue sample for molecular testing and helps guide treatment decisions [10].
Molecular Testing
Almost 95% of GISTs can be diagnosed through a combination of immunostaining (especially for KIT) and genetic testing for KIT or PDGFRA mutations which are essential in identifying the genetic mutations that drive tumor formation [7]. This step is important because it doesn’t just confirm the diagnosis—it can predict how the tumor will behave and respond to targeted therapies.
Treatment: Surgery and Smart Drugs
Surgical Resection
Gastrointestinal stromal tumors treated with surgery are the gold standard. If the tumor hasn’t spread and can be safely removed, that’s the best chance of a cure [3]. Surgeons aim to remove the tumor completely without rupturing it which can increase the risk of recurrence.
Targeted Therapies
The game-changer in GIST treatment was imatinib mesylate (also known as Gleevec). Tyrosine kinase inhibitors such as imatinib play a crucial role in treating GISTs by targeting specific proteins involved in tumor growth. This tyrosine kinase inhibitor (TKI) blocks the activity of the KIT protein, essentially turning off the faulty growth signal.
- For GIST patients with advanced or metastatic disease, imatinib has significantly improved survival rates [4].
- If the tumor becomes resistant to imatinib—something that can happen with certain secondary mutations—second- and third-line TKIs like sunitinib or regorafenib come into play [5].
Treatment is tailored based on:
- Tumor size
- Location
- Mitotic rate (how fast the cells are dividing)
- The type of mutation present [9]
Closing Thoughts
GISTs are a striking example of how a deeper understanding of tumor biology can completely change the way we approach cancer care. From the moment a suspicious mass is found on a scan to the precise tailoring of targeted therapies based on mutation testing, every step reflects a highly personalized, data-driven strategy.
As our knowledge of genes like ETV1, SDH, and others continues to expand, so too will the tools available to treat these complex tumors. GISTs may be rare, but the lessons they offer have far-reaching implications for cancer research, diagnostics, and therapeutics.
References
[1] Parab, T. M., DeRogatis, M. J., Boaz, A. M., Grasso, S. A., Issack, P. S., Duarte, D. A., Urayeneza, O., Vahdat, S., Qiao, J. H., & Hinika, G. S. (2019). Gastrointestinal stromal tumors: a comprehensive review. Journal of gastrointestinal oncology, 10(1), 144–154. https://doi.org/10.21037/jgo.2018.08.20
[2] Schaefer, I. M., Mariño-Enríquez, A., & Fletcher, J. A. (2017). What is New in Gastrointestinal Stromal Tumor?. Advances in anatomic pathology, 24(5), 259–267. https://doi.org/10.1097/PAP.0000000000000158
[3] Sugár, I., Forgács, B., István, G., Bognár, G., Sápy, Z., & Ondrejka, P. (2005). Gastrointestinal stromal tumors (GIST). Hepato-gastroenterology, 52(62), 409–413. https://pubmed.ncbi.nlm.nih.gov/15816446/
[4] Rammohan, A., Sathyanesan, J., Rajendran, K., Pitchaimuthu, A., Perumal, S. K., Srinivasan, U., Ramasamy, R., Palaniappan, R., & Govindan, M. (2013). A gist of gastrointestinal stromal tumors: A review. World journal of gastrointestinal oncology, 5(6), 102–112. https://doi.org/10.4251/wjgo.v5.i6.102
[5] Al-Share, B., Alloghbi, A., Al Hallak, M. N., Uddin, H., Azmi, A., Mohammad, R. M., Kim, S. H., Shields, A. F., & Philip, P. A. (2021). Gastrointestinal stromal tumor: a review of current and emerging therapies. Cancer metastasis reviews, 40(2), 625–641. https://doi.org/10.1007/s10555-021-09961-7
[6] Miettinen, M., & Lasota, J. (2003). Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Polish journal of pathology : official journal of the Polish Society of Pathologists, 54(1), 3–24.
[7] Mantese G. (2019). Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment. Current opinion in gastroenterology, 35(6), 555–559. https://doi.org/10.1097/MOG.0000000000000584
[8] Beham, A. W., Schaefer, I. M., Schüler, P., Cameron, S., & Ghadimi, B. M. (2012). Gastrointestinal stromal tumors. International journal of colorectal disease, 27(6), 689–700. https://doi.org/10.1007/s00384-011-1353-y
[9] Corless C. L. (2014). Gastrointestinal stromal tumors: what do we know now?. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 27 Suppl 1, S1–S16. https://doi.org/10.1038/modpathol.2013.173
[10] Shinomura, Y., Kinoshita, K., Tsutsui, S., & Hirota, S. (2005). Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors. Journal of gastroenterology, 40(8), 775–780. https://doi.org/10.1007/s00535-005-1674-0
[11] Zhao, X., & Yue, C. (2012). Gastrointestinal stromal tumor. Journal of gastrointestinal oncology, 3(3), 189–208. https://doi.org/10.3978/j.issn.2078-6891.2012.031
[12] Grande, C., & Haller, D. G. (2009). Gastrointestinal stromal tumors and neuroendocrine tumors. Seminars in oncology nursing, 25(1), 48–60. https://doi.org/10.1016/j.soncn.2008.10.004
